Although the appearance of
Doxil alleviated the
cardiotoxicity of DOX, the progression-free survival of patients was not prolonged compared with traditional medication regimens, and side effects such as
hand-foot syndrome has occurred. In order to solve this dilemma, we have designed a novel co-delivery strategy to construct a co-loaded
liposome of
berberine (BER) and
doxorubicin (DOX), which was called LipoBeDo. The optimal synergistic ratio of the two drugs was screened by cell cytotoxicity experiments in vitro, and the optimal attenuation ratio was further determined by in vivo cardiac H&E staining pathological sections. The optimal combination treatment caused a robust increase in apoptotic cells of 4T1, as compared to
drug alone treatment. The prepared co-loaded
liposome, LipoBeDo, had high encapsulation efficiency and good stability. The nanoliposome carrier controlled the
biological fate of the drugs and maintained a pre-defined optimal ratio in vivo. The LipoBeDo significantly inhibited
tumor growth in 4T1 murine mammary
carcinoma model compared with
Doxil (P < 0.05), and completely overcame the myocardial
rupture toxicity caused by
Doxil in mice. Our co-loaded
liposome delivery platform technology provided a new direction for the clinical treatment of
triple-negative breast cancer and the safe application of DOX.